Nifty
Sensex
:
:
17026.45
57107.15
-509.80 (-2.91%)
-1687.94 (-2.87%)

Pharmaceuticals & Drugs - Global

Rating :
32/99

BSE: 506197 | NSE: BLISSGVS

100.05
26-Nov-2021
  • Open
  • High
  • Low
  • Previous Close
  •  99.00
  •  102.75
  •  98.75
  •  99.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  276634
  •  279.12
  •  221.00
  •  91.65

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,038.33
  • 13.43
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,012.54
  • 0.50%
  • 1.22

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 33.19%
  • 7.58%
  • 27.60%
  • FII
  • DII
  • Others
  • 21.01%
  • 6.67%
  • 3.95%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.01
  • -6.28
  • -13.72

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.10
  • -12.06
  • -7.52

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 2.69
  • -3.55
  • -17.89

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.36
  • 18.77
  • 14.91

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.80
  • 2.56
  • 1.95

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.00
  • 8.75
  • 8.88

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Net Sales
195.99
129.55
51.29%
168.15
129.55
29.80%
132.05
119.80
10.23%
164.06
147.85
10.96%
Expenses
166.58
109.96
51.49%
133.54
110.07
21.32%
115.17
103.86
10.89%
125.78
114.90
9.47%
EBITDA
29.41
19.59
50.13%
34.60
19.48
77.62%
16.88
15.94
5.90%
38.28
32.95
16.18%
EBIDTM
15.00%
15.12%
20.58%
15.03%
12.79%
13.31%
23.33%
22.28%
Other Income
5.45
7.04
-22.59%
7.82
7.04
11.08%
6.33
18.66
-66.08%
4.12
5.52
-25.36%
Interest
0.68
1.94
-64.95%
1.40
1.83
-23.50%
2.36
4.55
-48.13%
0.94
1.08
-12.96%
Depreciation
4.30
4.29
0.23%
4.33
4.29
0.93%
4.27
3.34
27.84%
4.36
2.97
46.80%
PBT
29.89
20.41
46.45%
36.69
20.40
79.85%
16.58
13.33
24.38%
37.09
34.41
7.79%
Tax
7.83
3.75
108.80%
10.55
3.75
181.33%
8.43
7.76
8.63%
9.53
8.96
6.36%
PAT
22.06
16.65
32.49%
26.13
16.65
56.94%
8.15
5.57
46.32%
27.56
25.45
8.29%
PATM
11.25%
12.85%
15.54%
12.85%
6.17%
4.65%
16.80%
17.21%
EPS
2.05
1.57
30.57%
2.35
1.57
49.68%
0.61
0.85
-28.24%
2.48
2.30
7.83%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
660.25
577.21
689.31
898.57
814.64
798.44
546.89
407.13
344.64
396.63
267.07
Net Sales Growth
25.34%
-16.26%
-23.29%
10.30%
2.03%
46.00%
34.33%
18.13%
-13.11%
48.51%
 
Cost Of Goods Sold
361.01
328.90
439.97
612.26
391.13
358.93
237.18
152.77
132.01
167.90
145.83
Gross Profit
299.24
248.30
249.34
286.31
423.52
439.51
309.72
254.37
212.63
228.72
121.24
GP Margin
45.32%
43.02%
36.17%
31.86%
51.99%
55.05%
56.63%
62.48%
61.70%
57.67%
45.40%
Total Expenditure
541.07
470.56
565.99
740.93
617.50
595.70
391.17
303.70
273.42
285.47
195.73
Power & Fuel Cost
-
8.14
5.88
4.76
5.49
5.58
4.72
4.36
2.93
2.18
1.02
% Of Sales
-
1.41%
0.85%
0.53%
0.67%
0.70%
0.86%
1.07%
0.85%
0.55%
0.38%
Employee Cost
-
68.09
53.69
42.32
69.23
61.35
33.74
29.43
23.46
15.08
6.26
% Of Sales
-
11.80%
7.79%
4.71%
8.50%
7.68%
6.17%
7.23%
6.81%
3.80%
2.34%
Manufacturing Exp.
-
7.83
7.07
4.95
4.88
5.39
25.65
29.98
41.44
37.17
12.66
% Of Sales
-
1.36%
1.03%
0.55%
0.60%
0.68%
4.69%
7.36%
12.02%
9.37%
4.74%
General & Admin Exp.
-
12.03
13.27
17.05
39.48
36.36
24.68
17.07
15.16
14.63
7.36
% Of Sales
-
2.08%
1.93%
1.90%
4.85%
4.55%
4.51%
4.19%
4.40%
3.69%
2.76%
Selling & Distn. Exp.
-
31.35
28.83
34.72
62.09
92.46
42.51
47.05
35.12
40.26
21.13
% Of Sales
-
5.43%
4.18%
3.86%
7.62%
11.58%
7.77%
11.56%
10.19%
10.15%
7.91%
Miscellaneous Exp.
-
14.21
17.28
24.86
45.21
35.63
22.71
23.03
23.30
8.25
21.13
% Of Sales
-
2.46%
2.51%
2.77%
5.55%
4.46%
4.15%
5.66%
6.76%
2.08%
0.55%
EBITDA
119.17
106.65
123.32
157.64
197.14
202.74
155.72
103.43
71.22
111.16
71.34
EBITDA Margin
18.05%
18.48%
17.89%
17.54%
24.20%
25.39%
28.47%
25.40%
20.67%
28.03%
26.71%
Other Income
23.72
20.22
39.19
37.63
26.54
12.51
24.35
20.29
28.00
14.07
15.75
Interest
5.38
5.51
7.57
4.41
22.80
19.69
18.61
16.41
17.98
9.72
4.03
Depreciation
17.26
17.23
12.59
8.94
21.38
20.14
13.26
11.30
10.68
6.03
3.65
PBT
120.25
104.13
142.35
181.92
179.49
175.40
148.19
96.02
70.56
109.48
79.42
Tax
36.34
30.16
33.71
55.25
56.63
62.72
48.05
34.63
29.53
49.90
26.88
Tax Rate
30.22%
28.96%
26.14%
30.37%
38.98%
35.76%
32.42%
36.07%
41.85%
45.58%
33.85%
PAT
83.90
68.49
97.26
123.72
58.78
82.04
82.49
59.91
40.99
57.72
52.54
PAT before Minority Interest
77.31
73.97
95.25
126.66
88.66
112.68
100.15
61.39
41.03
59.58
52.54
Minority Interest
-6.59
-5.48
2.01
-2.94
-29.88
-30.64
-17.66
-1.48
-0.04
-1.86
0.00
PAT Margin
12.71%
11.87%
14.11%
13.77%
7.22%
10.28%
15.08%
14.72%
11.89%
14.55%
19.67%
PAT Growth
30.44%
-29.58%
-21.39%
110.48%
-28.35%
-0.55%
37.69%
46.16%
-28.98%
9.86%
 
EPS
8.11
6.62
9.40
11.95
5.68
7.93
7.97
5.79
3.96
5.58
5.08

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
808.25
735.61
646.00
536.24
486.62
412.62
337.08
286.88
258.01
210.66
Share Capital
10.31
10.31
10.31
10.31
10.31
10.31
10.31
10.31
10.31
10.31
Total Reserves
788.10
725.30
635.68
525.92
476.31
402.31
326.77
276.57
247.69
200.35
Non-Current Liabilities
45.24
46.32
37.99
12.92
32.81
49.55
67.52
95.65
96.92
39.34
Secured Loans
32.60
37.24
32.54
5.92
25.58
29.62
55.03
78.80
89.97
37.63
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
8.62
2.23
8.79
1.33
0.00
Long Term Provisions
2.50
2.44
1.75
1.91
2.05
1.81
1.40
1.10
0.74
0.51
Current Liabilities
203.64
230.53
207.03
299.40
437.09
378.97
242.68
307.66
202.19
59.74
Trade Payables
74.22
89.92
78.88
58.43
98.25
108.49
80.33
82.35
118.15
40.15
Other Current Liabilities
53.69
57.21
50.24
124.46
99.93
52.76
70.30
42.12
24.45
6.10
Short Term Borrowings
65.04
66.39
64.30
105.66
187.47
62.12
61.04
57.05
45.16
5.90
Short Term Provisions
10.69
17.01
13.61
10.85
51.45
155.60
31.00
126.14
14.44
7.58
Total Liabilities
1,076.79
1,027.22
904.88
860.04
1,022.90
874.24
662.17
700.35
570.92
309.74
Net Block
233.72
240.97
144.97
136.48
303.86
225.25
234.38
213.31
168.23
40.03
Gross Block
285.10
276.07
169.89
157.47
326.83
300.74
293.82
262.45
205.92
64.41
Accumulated Depreciation
51.38
35.10
24.92
20.99
22.97
75.48
59.44
49.14
37.69
24.38
Non Current Assets
311.59
257.48
211.39
170.25
456.97
291.23
244.66
229.67
219.61
100.21
Capital Work in Progress
2.39
0.00
46.74
0.47
4.03
9.10
0.00
4.33
0.65
6.91
Non Current Investment
0.70
0.72
0.72
6.30
1.05
0.11
0.01
0.01
0.01
0.00
Long Term Loans & Adv.
12.63
14.56
18.63
26.72
11.45
56.77
10.27
12.02
50.72
53.28
Other Non Current Assets
62.15
1.24
0.33
0.29
136.58
0.00
0.00
0.00
0.00
0.00
Current Assets
765.20
769.74
693.49
689.79
565.93
583.00
417.08
469.26
348.89
209.54
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.80
Inventories
98.93
74.14
77.37
59.03
49.30
38.67
33.70
32.53
32.52
12.68
Sundry Debtors
463.82
547.91
460.73
298.48
254.45
300.93
247.47
215.03
244.64
128.59
Cash & Bank
144.55
103.32
106.63
88.86
150.50
78.18
57.29
80.37
50.35
58.01
Other Current Assets
57.90
16.13
26.21
97.11
111.68
165.22
78.62
141.34
21.37
9.46
Short Term Loans & Adv.
35.78
28.24
22.55
146.30
78.44
149.92
60.69
130.30
8.92
5.09
Net Current Assets
561.56
539.21
486.47
390.39
128.84
204.03
174.40
161.60
146.70
149.80
Total Assets
1,076.79
1,027.22
904.88
860.04
1,022.90
874.23
662.17
700.35
570.91
309.75

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
63.97
46.70
39.95
17.64
289.47
112.95
48.94
41.15
6.50
35.46
PBT
104.13
128.97
181.91
179.49
175.40
148.19
96.02
70.56
109.48
79.42
Adjustment
46.29
26.85
-10.97
17.55
36.24
18.18
22.48
24.11
9.71
4.76
Changes in Working Capital
-57.89
-70.32
-183.07
-140.80
113.48
-8.33
-60.94
-19.30
-73.94
-37.83
Cash after chg. in Working capital
92.53
85.49
-12.13
56.24
325.13
158.05
57.56
75.36
45.25
46.35
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-28.56
-38.79
52.08
-38.61
-35.66
-45.10
-8.63
-34.21
-38.75
-10.89
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-46.99
-47.89
-73.52
50.24
-231.25
-49.84
-38.98
-10.90
-124.05
-21.91
Net Fixed Assets
-10.99
-65.98
-52.48
-1.04
42.08
-5.32
-28.78
-12.86
-12.91
-16.65
Net Investments
0.01
0.01
0.16
2.37
-0.95
-1.36
0.00
-0.01
-18.19
-1.03
Others
-36.01
18.08
-21.20
48.91
-272.38
-43.16
-10.20
1.97
-92.95
-4.23
Cash from Financing Activity
-20.80
-6.30
16.83
-75.98
-10.13
-40.25
-43.26
-8.47
109.89
26.48
Net Cash Inflow / Outflow
-3.82
-7.50
-16.74
-8.10
48.09
22.85
-33.31
21.77
-7.66
40.02
Opening Cash & Equivalents
15.34
15.04
36.95
47.41
0.00
5.09
49.57
27.79
58.01
17.98
Closing Cash & Equivalent
13.13
15.34
15.04
36.95
47.41
27.60
16.26
49.57
50.35
58.01

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
77.41
71.32
62.63
51.99
47.18
40.00
32.64
27.67
24.78
20.42
ROA
7.03%
9.86%
14.35%
9.42%
11.88%
13.04%
9.01%
6.46%
13.53%
20.09%
ROE
9.64%
13.79%
21.43%
17.34%
25.06%
26.73%
19.74%
15.17%
25.56%
27.85%
ROCE
12.29%
17.02%
26.58%
24.61%
31.06%
32.07%
23.57%
20.56%
36.18%
38.76%
Fixed Asset Turnover
2.06
3.09
5.49
3.37
2.56
1.85
1.47
1.48
2.95
5.09
Receivable days
319.89
267.05
154.20
123.80
126.33
182.13
206.07
241.81
171.03
169.17
Inventory Days
54.72
40.11
27.70
24.25
20.01
24.04
29.51
34.22
20.71
16.56
Payable days
91.08
56.62
35.01
51.74
67.63
95.25
108.77
148.76
105.12
67.61
Cash Conversion Cycle
283.53
250.53
146.89
96.31
78.70
110.92
126.81
127.26
86.63
118.11
Total Debt/Equity
0.15
0.16
0.16
0.22
0.46
0.32
0.47
0.60
0.58
0.21
Interest Cover
19.89
18.04
42.21
7.37
9.91
8.96
6.85
4.92
12.27
20.70

News Update:


  • Bliss GVS Pharma - Quarterly Results
    30th Oct 2021, 17:51 PM

    Read More
  • Bliss GVS Pharma purchases immovable property from JMFARC
    20th Sep 2021, 09:38 AM

    In this regard, the company has received Sale Confirmation Letter dated September 17, 2021 from JMFARC

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.